What type of study is this?

This is a In Vitro Study study.

September 5, 2025Cuadernos de Educación y DesarrolloOpen Access

Cannabidiol as a Green Adjuvant for Mupirocin-Based Formulations Against Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus

View Full Paper

Ask AI

Bookmark

The combination of cannabidiol and mupirocin significantly improved antibacterial activity against both MRSA and MSSA.
Synergistic effects confirmed by fractional inhibitory concentration index (FICI ≤ 0.5) and ≥ 4 log10 CFU/mL reduction.
In vitro assays demonstrated notable decreases in biofilm biomass and metabolic viability of S. aureus strains.
The findings point to the potential clinical utility of CBD-mupirocin formulations in managing resistant S. aureus skin infections.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

In vitro analysis shows enhanced antibacterial activity in CBD-mupirocin formulations, suggesting strong potential against resistant S. aureus strains.

Cite This Study

Guimarães et al. (2025) studied this question.

synapsesocial.com/papers/68bb3edf2b87ece8dc956e12 https://doi.org/10.55905/cuadv17n8-095

View Full Paper

Ask AI

Bookmark

Implication

In vitro analysis shows enhanced antibacterial activity in CBD-mupirocin formulations, suggesting strong potential against resistant S. aureus strains.

Cannabidiol as a Green Adjuvant for Mupirocin-Based Formulations Against Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus

Key Points

Discussion

Implication

Cite This Study

Cannabidiol as a Green Adjuvant for Mupirocin-Based Formulations Against Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading